Celyad SA Current Ratio 2014-2021 | CYAD

Celyad SA current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Celyad SA Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.02B $0.02B 1.32
2021-03-31 $0.02B $0.01B 1.42
2020-12-31 $0.02B $0.01B 1.67
2020-06-30 $0.03B $0.01B 2.73
2019-12-31 $0.05B $0.01B 3.59
2019-06-30 $0.04B $0.01B 3.98
2018-12-31 $0.06B $0.01B 5.36
2018-06-30 $0.08B $0.01B 6.61
2017-12-31 $0.04B $0.01B 4.58
2017-06-30 $0.08B $0.01B 5.53
2016-12-31 $0.09B $0.01B 7.58
2016-06-30 $0.10B $0.01B 9.48
2015-12-31 $0.12B $0.01B 9.53
2015-06-30 $0.14B $0.01B 14.62
2014-12-31 $0.04B $0.01B 5.45
2013-12-31 $0.03B $0.01B 6.67
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.067B $0.000B
Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71